Here is an email I sent Leo and Krishna today.
A partial summary of issues and question. I will post whatever response I get.
I'm sure some of my inquires might have already been addressed, but its what we see as part of what is holding CTIX back.
Happy New Year.
,
I hope that 2017 can be a happy new year for your shareholders too. The stock price is 35-40% lower than what it was at this time in 2013, 4 years ago and since then you both have received over $1.2- 1.4 million in salary and bonuses.
I'm sending this email because myself and friends who own over 1 million shares in CTIX seek clarification on why the stock is trading at these levels, market perception of CTIX management, and an assortment of questionable issues over the last 4 years.
For all the good that you do to move the trials forward you shoot yourselves in the 'foot' just as much. Here is a partial list of issues, concerns and open questions that we as large shareholders have; perhaps many other shareholders do as well.
It comes down to perception and appearances regarding these issues: Your current price point for CTIX is due to this perception.
1) The shady business with Aruda back in 2014 has been a big reason for low stock prices. Plus unanswered questions about the whole Aruda affair It has led to little buying power without Aruda doing more selling. Why were there no on going restrictions to his selling as part of the deal? Dr. Menon owes his shareholders explanations on what appears as shady/dishonest dealings with Aruda.
Why does Aruda not believe in the value of the company and hold? Interesting that he too lives in Boca?
2) Where is the follow up on K, where are the peer review papers? 4 years since the beginning of phase 1 at Dana-Farber and where is the assessment post phase 1 from Dana-Farber? Still on your website, is Dr. E. Frei's quote about K, how come no new quotes from those who did 4 years of testing on K. Is what Dr. Frei thinks about K prior to phase 1 relevant now? What matters now is detailed information on K post 4 years of phase one, where is it? What the heck are all those employees doing day to day to earn their salaries? Can't one write a paper for peer review? Is the up coming phase 2 based on anything more that the one woman's cancer regression back in 2015? What about the rest of the phase 1 participants who were receiving high doses of K, are they alive? What are the facts about them and if K did anything to help them live longer healthier lives? Is the lack of information to be interpreted as no additional information, and they all died? Did a change in P53 result in any difference in their lives? Plenty of time for a comprehensive review of K after 4 years, or is there nothing to write about? Is the new phase 2 just another bio 'hail mary' hope for something of value to show up? From your shareholders perspective, very little has been given to us as a follow through on Dana-Farber after a 4 year wait. Is the lack of information on patient follow up, articles, and comments from phase one doctors/technicians mean there is nothing additional to report since ASCO June 2015? Even with the higher doses used for the last months? Does P53 change mean anything beyond theory for prolonging lives and improving the quality of life for those participants receiving 500 to 750 doses of K?
Why is there no 'results' listed in the Clinical trail site: https://clinicaltrials.gov/ct2/show/NCT01664000
Why has there been no additional participation in cancer conferences as a presenter by you or Dana-Farber management? Does it all mean, no interest based on rather insignificant results? One person's cancer regression over 4 years without other clear results from other participants hardly means anything and hence no further papers or presentations?
3) Two years past the end of phase two for B and no phase 3 ever started, no FDA SPA? With the world in antibiotic crisis, how can we not have the FDA's interest? What is it about the company that the FDA is not willing to give the company the SPA?
4) The flip flops with B and P over the years. The on and off with P 'proof of concept' now its the lead drug?! It all looks so desperate, like 'not much happening in K or B, maybe we can run with P' ? Again appearances.
5) B UP proof of concept study, since it is open, why no regular updates on results? Yet, a tease PR after one of the first patients in Summer of 2016? Again without follow through it just looks like questionable tactics to attempt to setup a price increase for selling stocks for Aruda, Aspen or the company... We all like informational PR's, but follow through, otherwise it looks like there is not the same promising results to share. Yesterdays PR about OM is another example of a PR, sell into either by the company or the other two previously mentioned. Mentioning 'if our drug works it will be very valuable' is nonsense anyone could say the same and every Bio company does. If it works, means nothing, results mean something. Us desperate shareholders hope there is some hidden meaning in these statements, but after 5 years of the same, it has worn thin in its value, as experienced by every price decrease post PRs.. Appearance in the absence of verifiable facts is all that is left, and the company has worn out its market goodwill, as seen my the market lack of interest.
6)The ongoing uplisting and its mis-steps.
7) Then there is the issue of Dr. Menon's accident autumn 2015, what appears as another shady story regarding missed presentation, secret meetings and the such; which nothing has come out of.
Although we still hold the majority of our stock, these many questions offset other promising clinical trail progression. Obviously, the market also has questions about these or similar ones otherwise, after all these years there would be more buyers even with all the selling happening from Aruda, Aspen and the company.
Management is responsible for market perception.
We may be posting this to message boards for CTIX.
Sincerely,
A partial summary of issues and question. I will post whatever response I get.
I'm sure some of my inquires might have already been addressed, but its what we see as part of what is holding CTIX back.
Happy New Year.
,
I hope that 2017 can be a happy new year for your shareholders too. The stock price is 35-40% lower than what it was at this time in 2013, 4 years ago and since then you both have received over $1.2- 1.4 million in salary and bonuses.
I'm sending this email because myself and friends who own over 1 million shares in CTIX seek clarification on why the stock is trading at these levels, market perception of CTIX management, and an assortment of questionable issues over the last 4 years.
For all the good that you do to move the trials forward you shoot yourselves in the 'foot' just as much. Here is a partial list of issues, concerns and open questions that we as large shareholders have; perhaps many other shareholders do as well.
It comes down to perception and appearances regarding these issues: Your current price point for CTIX is due to this perception.
1) The shady business with Aruda back in 2014 has been a big reason for low stock prices. Plus unanswered questions about the whole Aruda affair It has led to little buying power without Aruda doing more selling. Why were there no on going restrictions to his selling as part of the deal? Dr. Menon owes his shareholders explanations on what appears as shady/dishonest dealings with Aruda.
Why does Aruda not believe in the value of the company and hold? Interesting that he too lives in Boca?
2) Where is the follow up on K, where are the peer review papers? 4 years since the beginning of phase 1 at Dana-Farber and where is the assessment post phase 1 from Dana-Farber? Still on your website, is Dr. E. Frei's quote about K, how come no new quotes from those who did 4 years of testing on K. Is what Dr. Frei thinks about K prior to phase 1 relevant now? What matters now is detailed information on K post 4 years of phase one, where is it? What the heck are all those employees doing day to day to earn their salaries? Can't one write a paper for peer review? Is the up coming phase 2 based on anything more that the one woman's cancer regression back in 2015? What about the rest of the phase 1 participants who were receiving high doses of K, are they alive? What are the facts about them and if K did anything to help them live longer healthier lives? Is the lack of information to be interpreted as no additional information, and they all died? Did a change in P53 result in any difference in their lives? Plenty of time for a comprehensive review of K after 4 years, or is there nothing to write about? Is the new phase 2 just another bio 'hail mary' hope for something of value to show up? From your shareholders perspective, very little has been given to us as a follow through on Dana-Farber after a 4 year wait. Is the lack of information on patient follow up, articles, and comments from phase one doctors/technicians mean there is nothing additional to report since ASCO June 2015? Even with the higher doses used for the last months? Does P53 change mean anything beyond theory for prolonging lives and improving the quality of life for those participants receiving 500 to 750 doses of K?
Why is there no 'results' listed in the Clinical trail site: https://clinicaltrials.gov/ct2/show/NCT01664000
Why has there been no additional participation in cancer conferences as a presenter by you or Dana-Farber management? Does it all mean, no interest based on rather insignificant results? One person's cancer regression over 4 years without other clear results from other participants hardly means anything and hence no further papers or presentations?
3) Two years past the end of phase two for B and no phase 3 ever started, no FDA SPA? With the world in antibiotic crisis, how can we not have the FDA's interest? What is it about the company that the FDA is not willing to give the company the SPA?
4) The flip flops with B and P over the years. The on and off with P 'proof of concept' now its the lead drug?! It all looks so desperate, like 'not much happening in K or B, maybe we can run with P' ? Again appearances.
5) B UP proof of concept study, since it is open, why no regular updates on results? Yet, a tease PR after one of the first patients in Summer of 2016? Again without follow through it just looks like questionable tactics to attempt to setup a price increase for selling stocks for Aruda, Aspen or the company... We all like informational PR's, but follow through, otherwise it looks like there is not the same promising results to share. Yesterdays PR about OM is another example of a PR, sell into either by the company or the other two previously mentioned. Mentioning 'if our drug works it will be very valuable' is nonsense anyone could say the same and every Bio company does. If it works, means nothing, results mean something. Us desperate shareholders hope there is some hidden meaning in these statements, but after 5 years of the same, it has worn thin in its value, as experienced by every price decrease post PRs.. Appearance in the absence of verifiable facts is all that is left, and the company has worn out its market goodwill, as seen my the market lack of interest.
6)The ongoing uplisting and its mis-steps.
7) Then there is the issue of Dr. Menon's accident autumn 2015, what appears as another shady story regarding missed presentation, secret meetings and the such; which nothing has come out of.
Although we still hold the majority of our stock, these many questions offset other promising clinical trail progression. Obviously, the market also has questions about these or similar ones otherwise, after all these years there would be more buyers even with all the selling happening from Aruda, Aspen and the company.
Management is responsible for market perception.
We may be posting this to message boards for CTIX.
Sincerely,
3
